Journal of International Oncology››2020,Vol. 47››Issue (2): 77-81.doi:10.3760/cma.j.issn.1673-422X.2020.02.003
• Original Articles •Previous ArticlesNext Articles
Ma Chao1,2, Cai Hongqing2, Zhang Minjie1,2, Ye Shilu1,2, Meng Xiaoli2, He Jie1, Wan Jinghai1,2()
Received:
2019-11-08Revised:
2019-12-29Online:
2020-02-08Published:
2020-05-27Contact:
Wan Jinghai E-mail:wanjinghai@sina.comMa Chao, Cai Hongqing, Zhang Minjie, Ye Shilu, Meng Xiaoli, He Jie, Wan Jinghai. Analysis of prognostic factors after surgical operation of lung cancer brain metastases[J]. Journal of International Oncology, 2020, 47(2): 77-81.
"
因素 | 例 数 | 中位 OS(月) |
95%CI | χ2值 | P值 |
---|---|---|---|---|---|
性别 | |||||
男 | 41 | 22.8 | 16.8~28.9 | 4.652 | 0.031 |
女 | 42 | 28.8 | 25.2~32.4 | ||
年龄(岁) | |||||
≤60 | 48 | 27.0 | 21.0~33.0 | 0.249 | 0.618 |
>60 | 35 | 27.6 | 20.0~35.1 | ||
吸烟史 | |||||
无 | 48 | 27.6 | 24.9~30.3 | 8.239 | 0.004 |
有 | 35 | 18.1 | 4.6~31.6 | ||
转移灶位置 | |||||
幕上 | 55 | 27.0 | 20.0~34.0 | 0.090 | 0.764 |
幕下/幕上幕下 | 28 | 26.4 | 20.2~32.6 | ||
颅内转移灶数目 | |||||
≤2 | 60 | 27.0 | 20.6~33.5 | 0.662 | 0.416 |
>2 | 23 | 26.4 | 15.0~33.7 | ||
术前KPS评分 | |||||
<70 | 11 | 22.8 | 7.6~38.0 | 1.754 | 0.062 |
≥70 | 72 | 27.0 | 21.7~32.3 | ||
颅外进展情况 | |||||
转移 | 13 | 22.8 | 6.4~39.2 | <0.001 | 0.998 |
无转移 | 70 | 27.0 | 22.2~32.0 | ||
Lung-molGPA评分 | |||||
<3 | 22 | 15.7 | 5.0~26.4 | 11.333 | 0.004 |
≥3 | 61 | 27.7 | 25.1~30.3 | ||
转移灶病理 | |||||
小细胞 | 9 | 10.6 | 4.9~16.4 | 11.799 | 0.001 |
非小细胞 | 74 | 26.6 | 26.0~29.2 | ||
术后有无辅助治疗 | |||||
有 | 68 | 27.7 | 25.5~30.0 | 8.735 | 0.003 |
无 | 15 | 15.7 | 0~32.4 | ||
术后是否靶向治疗 | |||||
是 | 36 | >27.7 | - | 13.697 | <0.001 |
否 | 47 | 21.9 | 14.1~30.0 | ||
术后是否放疗 | |||||
是 | 30 | 28.8 | 22.7~35.0 | 1.289 | 0.256 |
否 | 53 | 23.0 | 17.5~28.5 | ||
术后是否化疗 | |||||
是 | 37 | 26.4 | 20.6~32.1 | 0.070 | 0.792 |
否 | 46 | 27.6 | 20.5~35.5 |
[1] | Andrews DW, Scott CB, Sperduto PW , et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase Ⅲ results of the RTOG 9508 randomised trial[J]. Lancet, 2004,363(9422):1665-1672. DOI: 10.1016/S0140-6736(04)16250-8. |
[2] | Modi A, Vohra HA, Weeden DF . Does surgery for primary non-small cell lung cancer and cerebral metastasis have any impact on survival?[J]. Interact Cardiovasc Thorac Surg, 2009,8(4):467-473. DOI: 10.1510/icvts.2008.195776. |
[3] | Magnuson WJ, Lester-Coll NH, Wu AJ , et al. Management of brain metastases in tyrosine kinase inhibitor-naive epidermal growth factor receptor-mutant non-small-cell lung cancer: a retrospective multi-institutional analysis[J]. J Clin Oncol, 2017,35(10):1070-1077. DOI: 10.1200/JCO.2016.69.7144. |
[4] | 石远凯, 孙燕, 于金明 , 等. 中国肺癌脑转移诊治专家共识(2017年版)[J]. 中国肺癌杂志, 2017,20(1):1-12. DOI: 10.3779/j.issn.1009-3419.2017.01.01. |
[5] | 白皓, 韩宝惠 . 手术在非小细胞肺癌单发脑转移治疗中的作用分析[J]. 中国肺癌杂志, 2013,16(12):646-650. DOI: 10.3779/j.issn.1009-3419.2013.12.05. |
[6] | Li WY, Zhao TT, Xu HM , et al. The role of EGFR mutation as a prognostic factor in survival after diagnosis of brain metastasis in non-small cell lung cancer: a systematic review and meta-analysis[J]. BMC Cancer, 2019,19(1):145. DOI: 10.1186/s12885-019-5331-z. |
[7] | Lazaro T, Brastianos PK . Immunotherapy and targeted therapy in brain metastases: emerging options in precision medicine[J]. CNS Oncol, 2017,6(2):139-151. DOI: 10.2217/cns-2016-0038. |
[8] | 路长红, 马莉, 孙增峰 , 等. 非小细胞肺癌脑转移手术治疗预后相关因素分析[J]. 中华肿瘤防治杂志, 2016,23(10):677-681. DOI: 10.16073/j.cnki.cjcpt.2016.10.013. |
[9] | Kubota K . I. Management of brain metastasis in patients with lung cancer[J]. Gan To Kagaku Ryoho, 2017,44(6):475-478. |
[10] | Sperduto PW, Yang TJ, Beal K , et al. Estimating survival in patients with lung cancer and brain metastases: an update of the graded prognostic assessment for lung cancer using molecular markers (Lung-molGPA)[J]. JAMA Oncol, 2017,3(6):827-831. DOI: 10.1001/jamaoncol.2016.3834. |
[1] | Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou.Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer[J]. Journal of International Oncology, 2024, 51(6): 321-325. |
[2] | Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei.Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma: a real-world clinical study[J]. Journal of International Oncology, 2024, 51(6): 326-331. |
[3] | Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337. |
[4] | Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua.Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy[J]. Journal of International Oncology, 2024, 51(5): 257-266. |
[5] | Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279. |
[6] | Liu Pingping, He Xuefang, Zhang Yi, Yang Xu, Zhang Shanshan, Ji Yifei.Risk factors of postoperative recurrence in patients with primary brain glioma and prediction model construction[J]. Journal of International Oncology, 2024, 51(4): 193-197. |
[7] | Wan Fang, Yang Gang, Li Rui, Wan Qijing.Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer[J]. Journal of International Oncology, 2024, 51(4): 204-209. |
[8] | Yao Yixin, Shen Yulin.Predictive value of serum SOCS3 and TXNIP levels for the prognosis of patients with hepatocellular carcinoma treated with TACE[J]. Journal of International Oncology, 2024, 51(4): 217-222. |
[9] | Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao.Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes[J]. Journal of International Oncology, 2024, 51(3): 143-150. |
[10] | Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan.Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer[J]. Journal of International Oncology, 2024, 51(3): 175-180. |
[11] | Peng Qin, Cai Yuting, Wang Wei.Advances on KPNA2 in liver cancer[J]. Journal of International Oncology, 2024, 51(3): 181-185. |
[12] | Chen Boguang, Wang Sugui, Zhang Yongjie.Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer[J]. Journal of International Oncology, 2024, 51(2): 73-82. |
[13] | Jin Xudong, Chen Zhongjian, Mao Weimin.Research progress on the role of MTAP in malignant mesothelioma[J]. Journal of International Oncology, 2024, 51(2): 99-104. |
[14] | He Jiahui, Hu Qinyong.Comparative analysis of lung cancer incidence and mortality trends and risk factors in China and the United States based on GBD data[J]. Journal of International Oncology, 2024, 51(1): 29-36. |
[15] | Huang Zhen, Chen Yongshun.Research progress of circulating tumor DNA in the diagnosis and treatment of hepatocellular carcinoma[J]. Journal of International Oncology, 2024, 51(1): 59-64. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||